

LIST OF TABLES

Table No.	Table captions	Page No.
Chapter 2		
2.1	Classification of Periodontitis (Armitage, 1999)	13
2.2	Comparison of localized intrapocket delivery and systemic delivery (Yadav <i>et al.</i> , 2015)	21
2.3	Marketed intrapocket drug delivery systems	23
2.4	Benefits and limitations of commonly used localized drug delivery systems	24
2.5	Literature survey of microspheres based periodontal drug delivery	33
2.6	Different polymers used in the formulation of thermosensitive in-situ gel system	36
2.7	Literature survey of in-situ gelling systems in the management of periodontitis	37
2.8	Literature survey of the studies done on ornidazole.	43
2.9	Recent literature survey of doxycycline for the management of periodontitis	46
2.10	Literature survey of studies done on chitosan-based drug delivery systems.	49
2.11	Literature survey of studies done on role of sodium alginate in drug delivery system.	52
2.12	Difference between physical properties of Pluronic F127 and Pluronic F68.	54
2.13	Literature survey of applications of pluronics or poloxamers in drug delivery systems.	55
2.14	Literature survey of research done on tripolyphosphate based drug delivery systems.	57
2.15	Literature survey of applications of glutaraldehyde in drug delivery systems.	60
2.16	Literature survey of applications of vanillin in drug delivery systems.	62

Chapter 3		
3.1	List of materials used	68
3.2	List of equipment used.	69
3.3	List of softwares used	69
Chapter 4		
4.1	Absorptivity and Molar absorptivity of drugs at respective wavelengths.	80
4.2	Data of Intraday recovery and precision studies by Method I and Method II.	81
4.3	Data of Interday recovery and precision studies by Method I and Method II.	81
4.4	Summary of validation parameters for Method I and Method II.	83
4.5	Analysis of synthetic mixture of OZ and DX.	84
4.6	Solubility of ornidazole and doxycycline in Phosphate buffer pH 6.8.	86
Chapter 5		
5.1	Independent fabrication variables and dependent response variables associated with CS-Ca-SA microsphere formulation.	88
5.2	Independent factors and dependent factors associated with CSTPP microsphere formulation.	99
5.3	Formulation design of CS crosslinked microspheres.	102
5.4	Box-Behnken Experimental Design for the formulation of chitosan-vanillin crosslinked microspheres.	105
5.5	Plackett-Burman Factorial Design for fabrication of CS-Ca-SA microspheres and corresponding experimental results.	111
5.6	Summary of ANOVA results and regression parameters	114
5.7	Comparison of predicted and experimental values for validation of model	116
5.8	Drug release kinetics of OZ and DX from CS-Ca-SA and Ca-SA microspheres.	118
5.9	Stability parameters obtained after six months of storage at different storage conditions.	131

5.10	A 12 run Plackett-Burman factorial design for fabrication of tripolyphosphate crosslinked chitosan microspheres.	134
5.11	Summary of ANOVA of Plackett-Burman factorial design batches.	135
5.12	Predicted and experimental values of responses for optimized batch of microspheres.	140
5.13	Release kinetics of drugs from optimized CSTPP microspheres.	142
5.14	Stability study of CSTPP microspheres after storage of 6 months	151
5.15	A 12 run Plackett-Burman factorial Design of chitosan microspheres	152
5.16	Model Summary and ANOVA results.	153
5.17	Theoretical and experimental values of responses and their validation.	156
5.18	Comparative drug release kinetics of CSV and CSG microspheres.	158
5.19	Box-Behnken Experimental Design with obtained responses.	169
5.20	Model Summary and ANOVA results	170
5.21	Validation of optimized variables for microspheres	173
Chapter 6		
6.1	Box-Behnken Experimental Design for the formulation of MLIG.	175
6.2	Preclinical treatment groups and evaluation parameters for ligature induced periodontal (LIP) model.	182
6.3	Semi-quantitative scoring of clinical parameters.	184
6.4	Experimental runs and dependent response variables for MLIG.	187
6.5	ANOVA results for MLIG	187
6.6	Validation of optimized variables for MLIG formulations	189
6.7	Drug release kinetics from optimized MLIG formulations.	191
6.8	Stability studies of optimized MLIG formulations after sterilization and storage at refrigerated condition.	199

